Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
CuriosityStream | CURI | Sep 19, 2024 | 1.80 | -2.17 |
Curis | CRIS | Sep 19, 2024 | 5.93 | +1.19 |
CURRENC Group | CURR | Sep 19, 2024 | 3.01 | 0.00 |
Curtiss-Wright | CW | Sep 19, 2024 | 317.98 | +1.40 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Sep 19, 2024 | 43.13 | +0.64 |
Cushman & Wakefield | CWK | Sep 19, 2024 | 13.72 | +1.86 |
Custom Truck One Source | CTOS | Sep 19, 2024 | 3.84 | +2.13 |
Customers Bancorp | CUBI | Sep 19, 2024 | 49.52 | +2.25 |
Customers Bancorp E Pref | CUBI-E | Sep 19, 2024 | 25.39 | +0.55 |
Customers Bancorp F Pref | CUBI-F | Sep 19, 2024 | 25.24 | +0.33 |
Cutera | CUTR | Sep 19, 2024 | 0.77 | +1.01 |
CVB Financial | CVBF | Sep 19, 2024 | 18.57 | +2.48 |
CVD Equipment | CVV | Sep 19, 2024 | 3.35 | +0.60 |
CVR Energy | CVI | Sep 19, 2024 | 24.60 | +2.80 |
Cvr Partners LP Unit | UAN | Sep 19, 2024 | 70.35 | +0.56 |
CVRx | CVRX | Sep 19, 2024 | 9.25 | +6.44 |
CVS Health | CVS | Sep 19, 2024 | 58.40 | -0.03 |
CXApp A | CXAI | Sep 19, 2024 | 1.75 | -2.23 |
CyberArk Software | CYBR | Sep 19, 2024 | 271.23 | +1.19 |
Cybin | CYBN | Sep 19, 2024 | 8.56 | +4 096.08 |
Cyclacel Pharmaceuticals | CYCC | Sep 19, 2024 | 1.02 | -2.39 |
Cyclacel Pharmaceuticals Pref | CYCCP | Sep 19, 2024 | 7.00 | 0.00 |
Cyclerion Therapeutics | CYCN | Sep 19, 2024 | 2.83 | +0.71 |
Cyclo Therapeutics | CYTH | Sep 19, 2024 | 0.68 | +5.18 |
Cyngn | CYN | Sep 19, 2024 | 3.75 | -1.57 |
Cytek Biosciences | CTKB | Sep 19, 2024 | 5.29 | +4.55 |
Cytokinetics | CYTK | Sep 19, 2024 | 55.60 | -0.61 |
Cytomed Therapeutics | GDTC | Sep 19, 2024 | 1.55 | -1.27 |
CytomX Therapeutics | CTMX | Sep 19, 2024 | 1.17 | -1.68 |
Cytosorbents | CTSO | Sep 19, 2024 | 1.42 | 0.00 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.